BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

China Clears IND For Harbour BioMed And Kelun Biotech Bispecific Antibody For Atopic Dermatitis

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology an...

March 10, 2026 | News

Leads Biolabs Doses First Patient In Phase II Trial Of PD L1 4 1BB Bispecific Antibody For Esophageal Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has bee...

March 10, 2026 | News

Insilico Medicine AI Discovered CKD Anemia Drug ISM4808 Enters Phase I Clinical Trial

Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced th...

March 09, 2026 | News

Akeso Reports Durable Long Term Survival Benefit Of Cadonilimab In Advanced Cervical Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II ...

March 06, 2026 | Report

Thermo Fisher Opens Advanced Distribution And Labelling Centre In Uppsala To Strengthen Global Immunodiagnostics Supply

Thermo Fisher Scientific Inc., the world leader in serving science, announced the opening of a new 8,000-square-meter distribution and labeling center supp...

March 05, 2026 | News

Senhwa Biosciences And CellType Partner To Advance AI Driven Development Of CX 4945 Cancer Therapy

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and inf...

March 05, 2026 | News

Antengene Grants UCB Global Rights To Develop And Commercialise ATG 201 Bispecific T Cell Engager

Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, t...

March 05, 2026 | News

XellSmart Secures Fourth Dual US And China Regulatory Clearance For iPSC Derived Cell Therapy In Multiple System Atrophy

XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for P...

March 04, 2026 | News

XtalPi And ReviR Dose First Participant In Phase One Trial Of RTX 117 For Rare Neurological Disorders

RTX-117 is an investigational small molecule designed to modulate the Integrated Stress Response (ISR) pathway, with the goal of restoring protein transl...

March 04, 2026 | News

Ono Pharmaceutical And Congruence Expand Research Alliance Into Neurology And Immunology

Expanded collaboration continues to leverage Congruence's proprietary computational drug discovery engine, Revenir™ to deliver Development Candi...

March 04, 2026 | News

Hua Medicine Secures First Glucokinase Activator Approval Outside Mainland China In Hong Kong

First glucokinase-activator (GKA) approval outside mainland China Approval supports a differentiated approach to Type 2 diabetes (T2D) ma...

March 04, 2026 | News

Innovent Secures China Approval For Jaypirca In Previously Treated CLL And SLL

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

March 03, 2026 | News

Lynk Pharmaceuticals Reports Positive Phase III Results For Zemprocitinib In Atopic Dermatitis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammat...

March 03, 2026 | News

Genentech Reports Phase III Success For Fenebrutinib With 51 Percent Relapse Reduction In Multiple Sclerosis

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relap...

March 03, 2026 | News

Stay Connected